Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Triple Negative Breast Neoplasms × Doxorubicin × Clear all

Status

Sponsor Class

Study Type

Interventional 41 Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 7 Lymphoma 2 Cardiotoxicity 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Sarcoma 1 Pseudomyxoma Peritonei 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Peritoneal Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neurotoxicity Syndromes 1 Neoplasm, Residual 1 Mesothelioma 1 Lymphoma, Follicular 1 Fatigue 1 Fallopian Tube Neoplasms 1 Desmoid Tumors 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Hepatocellular 1 Breast Cancer Organoids 1 Appendiceal Neoplasms 1

Interventions

Blood Specimen Collection 4 Drug Therapy 3 Specimen Handling 2 Immune Checkpoint Inhibitors 2 Carboplatin 2 Biopsy, Large-Core Needle 2 Biopsy 2 toripalimab 1 tislelizumab 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 Zoledronic Acid 1 Prophylactic Mastectomy 1 Paracentesis 1 Neuropsychological Tests 1 Mifepristone 1 Medicine, Chinese Traditional 1 Mastectomy, Segmental 1 Magnetic Resonance Spectroscopy 1 Magnetic Resonance Imaging 1 Interviews as Topic 1 Immunotherapy 1 Immunohistochemistry 1 Gene Expression Profiling 1 Doxorubicin 1 DNA 1 Cyclophosphamide 1 Combined Modality Therapy 1 Colonoscopy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06965361 2025-05-16

TIL; PD1; PDL1

Ziauddin University

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡